<DOC>
	<DOCNO>NCT00815100</DOCNO>
	<brief_summary>The purpose study investigate whether pure heart rate-lowering agent ( Ivabradine ) reduce vascular inflammatory stress patient acute coronary syndrome</brief_summary>
	<brief_title>Effects Ivabradine Reduction Inflammatory Markers Patients With Acute Coronary Syndrome</brief_title>
	<detailed_description>The activation inflammatory pathway play important contributory role coronary plaque instability subsequent rupture , lead development acute coronary syndrome . Elevated level serum inflammatory marker high-sensitivity C-reactive protein ( hs-CRP ) represent independent risk factor cardiovascular event . Raised rest heart rate ( HR ) show associated cardiovascular event . Ivabradine new HR-reducing agent , demonstrate antianginal anti-ischemic property patient stable angina . In atherosclerosis model , selective HR reduction ivabradine show decrease marker vascular oxidative stress , improve endothelial function , reduce atherosclerotic plaque formation . We hypothesize addition ivabradine standard medical therapy beneficial effect marker inflammatory stress acute coronary syndrome patient .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Acute Coronary Syndrome</mesh_term>
	<criteria>1 . Male female . 2 . Age &gt; 18 year . 3 . Ischemic symptom suspect represent nonST segment elevation acute coronary syndrome define : Clinical history consistent new onset , worsen pattern , characteristic ischemic chest pain occur rest minimal exertion ( lasting longer 10 min ) plan manage early invasive strategy intention perform percutaneous coronary intervention early possible later 72 hour randomization , least one following : 1 . ECG change compatible new ischemia ( ST depression least 1 mm transient ST elevation ST elevation &lt; 1 mm T wave inversion &gt; 3 mm least 2 contiguous lead ; 2 . Already elevated cardiac enzyme ( eg , CKMB ) biomarkers ( troponin I T ) upper limit normal . 4 . Patients sinus rhythm rest HR &gt; 60 beat per minute rest standard 12lead ECG . 5 . Written inform consent obtain . 1 . Patients unlikely cooperate study inability unwillingness give inform consent . 2 . Pregnant breastfeed woman woman childbearing potential . 3 . Patients recent ( &lt; 6 month ) myocardial infarction coronary revascularization history stroke cerebral transient ischemic attack within precede 3 month schedule revascularization ( percutaneous coronary intervention coronary artery bypass graft ) . 4 . Patients least 1 follow criterion : Implanted pacemaker implantable cardioverter defibrillator . Valvular disease likely require surgery within next 2 year . Sick sinus syndrome , sinoatrial block , congenital long QT syndrome , complete atrioventricular block . Expectation death illness course trial . Known severe liver renal disease . Requiring likely require follow medication : macrolide antibiotic , cyclosporin , gestodene , antiretroviral drug azole antifungal ketoconazole known hereditary problem galactose intolerance , Lapp lactase deficiency , glucosegalactose malabsorption . 5 . Patients systemic cardiac inflammatory process exception atherosclerosis .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>April 2011</verification_date>
	<keyword>Ivabradine</keyword>
	<keyword>Acute coronary syndrome .</keyword>
	<keyword>Inflammation</keyword>
	<keyword>C-reactive protein</keyword>
	<keyword>Atherosclerosis</keyword>
</DOC>